Loading...

CRBU CARIBOU BIOSCIENCES INC Company Mergers 8-K Filing

CRB

CRB

CARIBOU BIOSCIENCES INC

(CRBU)

2026 8-K

FDA Designation Received

Financial Results Announcement

Financial Results Report

Financial Results Announced

Reverse Stock Split

Financial Statements

Management Changes

Financial Results

Clinical Updates

CFO Appointment

Financial Results

Management Change

CFO Resignation

Management Change

Financial Results Announcement

Financial Condition and Wor...

Annual Meeting Results

Clinical Trial Update

Financial Results Announcement

FDA Clearance for CB-010 IN...

Financial Results Announcement

Appointment of Chief Techno...

Departure of Chief Medical ...

Departure of Chief Medical ...

FDA Clearance for CB-012 CA...

Financial Results Announcement

Underwriting Agreement

Annual Meeting Results

Financial Results Announcement

FDA Fast Track Designation ...

Phase 1 Trial Initiation

Annual Meeting Announcement

Financial Results Announcement

External Links:

On March 31, 2026, Caribou Biosciences, Inc. announced it received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its CB-011 therapy targeting relapsed or refractory multiple myeloma. This therapy is currently being evaluated in a phase 1 clinical trial.

AI Assistant

CARIBOU BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.